Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
65
-
Total 13F shares, excl. options
-
26M
-
Shares change
-
-1.43M
-
Total reported value, excl. options
-
$524M
-
Value change
-
-$46.6M
-
Number of buys
-
28
-
Number of sells
-
-35
-
Price
-
$20.17
Significant Holders of Jade Biosciences, Inc. - COM (AVTE) as of Q1 2023
75 filings reported holding AVTE - Jade Biosciences, Inc. - COM as of Q1 2023.
Jade Biosciences, Inc. - COM (AVTE) has 65 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (8.26M shares), Sofinnova Investments, Inc. (3.76M shares), Atlas Venture Life Science Advisors, LLC (2.04M shares), BAKER BROS. ADVISORS LP (1.96M shares), Cormorant Asset Management, LP (1.56M shares), TCG Crossover Management, LLC (1.08M shares), VR Adviser, LLC (834K shares), ORBIMED ADVISORS LLC (757K shares), GREAT POINT PARTNERS LLC (756K shares), and Octagon Capital Advisors LP (622K shares).
This table shows the top 65 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.